Zehua Zhong

Neoadjuvant therapy and minimally invasive surgery for pancreatic cancer: current evidence and surgical decision-making

Neoadjuvant therapy (NAT) is standard care for borderline resectable and locally advanced pancreatic cancer (PC). While minimally invasive surgery (MIS) is increasingly utilized post-NAT, surgical decision-making and technical feasibility remain debated. This review evaluates cur...